Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-13
DOI
10.1007/s40259-022-00545-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution
- (2022) Louise C. Druedahl et al. PLoS One
- Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States
- (2021) Kyle Herndon et al. BIODRUGS
- Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
- (2021) Liese Barbier et al. Journal of Pharmaceutical Policy and Practice
- Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
- (2021) Jingyan Yang et al. BIODRUGS
- Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim
- (2020) Mariana P. Socal et al. VALUE IN HEALTH
- The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
- (2020) Hye-Na Kang et al. BIOLOGICALS
- Physicians’ perceptions of the uptake of biosimilars: a systematic review
- (2020) Kati Sarnola et al. BMJ Open
- European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
- (2020) Liese Barbier et al. BIODRUGS
- Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage
- (2019) Pinar Karaca-Mandic et al. HEALTH AFFAIRS
- Biosimilars: Review of current applications, obstacles, and their future in medicine
- (2018) Flyn Kaida-Yip et al. World Journal of Clinical Cases
- Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition
- (2018) Brian K. Chen et al. DRUGS
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
- (2016) Hillel Cohen et al. ADVANCES IN THERAPY
- Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey
- (2016) Morgane Beck et al. mAbs
- Using the framework method for the analysis of qualitative data in multi-disciplinary health research
- (2013) Nicola K Gale et al. BMC Medical Research Methodology
- Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database
- (2013) Wen-Shyong Liou et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?
- (2012) Vittorio Modena et al. AUTOIMMUNITY REVIEWS
- The economic pressures for biosimilar drug use in cancer medicine
- (2012) Paul Cornes Targeted Oncology
- Physician Perceptions About Generic Drugs
- (2011) William H Shrank et al. ANNALS OF PHARMACOTHERAPY
- Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review
- (2011) Marissa A. Blum et al. CLINICAL THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started